What's Going On With Small Cap Cancer Vaccine Focused Gritstone Bio Stock On Tuesday?
What's Going On With Small Cap Cancer Vaccine Focused Gritstone Bio Stock On Tuesday?
Tuesday, Gritstone Bio Inc (NASDAQ:GRTS) released preliminary data from the ongoing, signal-seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC).
週二，Gritstone Bio Inc（納斯達克股票代碼：GRTS）公佈了正在進行的、尋求信號的第2期研究的初步數據，該研究評估了其針對一線轉移性微衛星穩定結直腸癌（MSS-CRC）的個性化新抗原癌症疫苗GRANITE。
The study is designed to quantify the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902) in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone.
該研究旨在量化GRANITE（GRT-C901/GRT-R902）與免疫檢查點阻斷聯合使用維持療法以及氟嘧啶/貝伐珠單抗與單獨使用氟嘧啶/貝伐珠單抗相比的臨床益處。
Overall progression-free survival (PFS) data show an early trend in benefit for GRANITE patients with a hazard ratio of 0.82 and extended PFS benefit in high-risk patients with a hazard ratio of 0.52, in whom progression occurs faster.
總體無進展生存（PFS）數據顯示，危害比爲0.82的GRANITE患者的總體無進展存活率（PFS）受益呈早期趨勢，而危害比爲0.52、進展更快的高危患者，PFS受益延長。
Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis did not demonstrate a difference between study arms.
數月治療期間的循環腫瘤DNA（ctDNA）分析顯示出與疾病進展的預期關係，有利於GRANITE，而短期ctDNA反應分析並未顯示研究組之間的差異。
Gritstone bio manufactured the GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).
Gritstone bio爲每位符合條件的患者生產了GRANITE候選產品（即疫苗生產成功率爲100％）。
GRANITE demonstrated a favorable safety and tolerability profile. Common AEs were mild systemic and local effects typically associated with any potent vaccine (i.e., transient flu-like illness). No patients discontinued study treatment due to an AE.
GRANITE 表現出良好的安全性和耐受性。常見的不良反應是輕微的全身和局部效應，通常與任何強效疫苗（即短暫性流感樣疾病）有關。沒有患者因 AE 而停止研究治療。
Concurrently, on Monday, Gritstone bio priced the approximately $32.5 million underwritten public offering of 8.33 million shares and accompanying common warrants to purchase 8.33 million shares at a combined price of $1.50.
同時，週一，Gritstone bio對約3,250萬美元的承銷公開發行833萬股及隨附的普通認股權證進行了定價，將以1.50美元的合併價格購買833萬股股票。
Last month, Gritstone bio announced an approximately 40% reduction of its workforce.
上個月，Gritstone bio宣佈裁員約40％。
The move comes following the recently announced delay of the proposed CORAL Phase 2b study, which resulted in Gritstone not receiving the external funding it previously anticipated, beginning in the first quarter of 2024, associated with the initiation of the study.
此舉是在最近宣佈推遲擬議的CORAL 2b期研究之後採取的，這導致Gritstone從2024年第一季度開始沒有收到其先前預期的與啓動該研究相關的外部資金。
Price Action: GRTS shares are down 43% at $1.34 on the last check Tuesday.
價格走勢：在週二的最後一次支票中，GRTS股價下跌43％，至1.34美元。
Photo via Shutterstock
照片來自 Shutterstock
譯文內容由第三人軟體翻譯。